Wird geladen...
The use of natalizumab for multiple sclerosis
Natalizumab is a monoclonal antibody that acts as an α4 integrin antagonist to prevent leukocyte trafficking into the central nervous system. It is US Food and Drug Administration (FDA) approved for the treatment of relapsing–remitting multiple sclerosis (RRMS). Natalizumab demonstrated high efficac...
Gespeichert in:
| Veröffentlicht in: | Neuropsychiatr Dis Treat |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Dove Medical Press
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5499927/ https://ncbi.nlm.nih.gov/pubmed/28721050 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S114636 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|